How do I set a price alert for NXTG.TA?

To set a NXTG.TA price alert on Stock Alarm Pro, navigate to the NXTG.TA quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for NXTG.TA?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for NXTG.TA. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for NXTG.TA?

Stock Alarm Pro supports over 125 trigger types for NXTG.TA: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about NXTG.TA price changes?

NXTG.TA alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for NXTG.TA alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for NXTG.TA and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

NXTG.TA Company Intelligence - Business Model, Drivers & Risks

NXTG.TA(NXTG.TA)

$40.90—Stale · unknown old

WatchlistAsk SA Chart

NXTG.TA(NXTG.TA)

TLV • Last print unknown ago

$40.90—Stale · unknown old

WatchlistAsk SA Chart Studio

NXTG.TA(NXTG.TA)

NXTG.TA

Nextage Therapeutics Ltd is a biotechnology company focused on developing innovative therapies for rare genetic disorders. The company is particularly noted for its proprietary gene-editing technology, which has shown promise in preclinical trials for conditions such as Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA). Its competitive position is bolstered by strategic partnerships with leading academic institutions in Israel and Europe, enhancing its research capabilities.

HealthcareDrug Manufacturers - Specialty & Genericlow - The company operates with high fixed costs associated with R&D and clinical trials, while revenue generation is still in the early stages, leading to significant operational losses.

Business Overview

01Research grants and collaborations with academic institutions (estimated 60%)

02Licensing agreements for proprietary technology (estimated 30%)

03Potential future product sales (estimated 10%)

Nextage generates revenue primarily through research grants and collaborations, leveraging its gene-editing technology. The company has established partnerships that provide funding and resources for R&D, while also positioning itself for future licensing deals once products reach commercialization. Its competitive advantage lies in its innovative gene-editing platform, which is designed to address unmet medical needs in rare diseases.

What Moves the Stock

Progress in clinical trials for DMD and SMA therapies

Partnership announcements with pharmaceutical companies

Regulatory approvals for new therapies

Market sentiment towards biotech sector developments

Watch on Earnings

Clinical trial milestonesPartnership revenue updatesCash burn rate

Risk Factors

Regulatory changes affecting gene-editing technologies

Technological disruption from competing gene-editing platforms

Emergence of alternative therapies for DMD and SMA

Increased competition from larger biotech firms with more resources

High debt levels relative to equity, which could strain financial flexibility

Negative operating cash flow impacting liquidity

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - The biotechnology sector can be sensitive to economic cycles, particularly in terms of funding availability for R&D and consumer spending on healthcare.

Interest Rates

Higher interest rates could increase the cost of capital for Nextage, impacting its ability to finance R&D and clinical trials. This could also affect investor sentiment and valuation multiples.

Credit

minimal - The company is not heavily reliant on credit markets, but its operational cash flow issues could limit access to financing.

Live Conditions

Russell 2000 FuturesS&P 500 FuturesDow Jones Futures